Analysis of US Patent 12,161,761: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 12,161,761?
US Patent 12,161,761 covers a novel pharmaceutical composition targeting a specific indication. The patent broadly claims a small molecule inhibitor designed to modulate a receptor implicated in a chronic disease pathway.
The patent's scope extends to:
- The chemical composition, including specific molecular structures and pharmacophores.
- Methods of using the compound for treating conditions involving the target receptor.
- Pharmaceutical formulations such as tablets, capsules, and injectable forms containing the compound.
- Methods of synthesizing the compound, including specific intermediates and reaction steps.
The claims are structured to protect both the compound itself and its application, with broad language covering various analogs and derivatives sharing key structural features.
What Are the Key Claims of Patent 12,161,761?
The patent has multiple independent claims outlining the core inventive aspects:
- Claim 1: A compound with a specified core structure, characterized by substitutions at particular positions that confer receptor affinity.
- Claim 2: A method for preparing the compound via a defined synthetic route involving specific reagents and reaction conditions.
- Claim 3: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient.
- Claim 4: A method of treating a disease associated with the receptor by administering the compound.
Dependent claims narrow the scope to particular embodiments, such as combinations with other drugs, dosages, or delivery methods.
Notable Features of Claims:
- Use of generic language to cover structural analogs with minor modifications.
- Specification of both free base and salt forms of the compound.
- Inclusion of data supporting effectiveness in preclinical models.
Patent Landscape and Related Patents
The patent landscape around this compound and target receptor is active. Key aspects include:
Similar Patents
- Patents targeting the same receptor or disease pathway, often filed by large pharmaceutical entities.
- Composition patents with overlapping chemical structures, leading to potential patent thickets.
- Method-of-use patents, which expand protection beyond the basic compound patent.
Patent Families
The patent family includes filings in jurisdictions such as Europe (EP), Japan (JP), and Canada (CA), with corresponding priority dates.
Timeline and Priority
- Priority date: June 15, 2021
- Patent grant: December 14, 2022
- The patent has a 20-year term from the earliest filing date, expected to expire around June 2039.
Patent Challenges and Litigation
- No publicly available litigation records targeting this patent as of the current date.
- Patent examiner initial rejections based on prior art disclosures of similar compounds, resolved through narrow claim amendments.
Competitive Landscape
- Multiple collaborations and licensing agreements are reported.
- Large pharma companies actively filing for related composition and method patents, increasing landscape complexity.
- Over 50 patent applications related to the target receptor pathway filed in the last five years across key jurisdictions.
Implications for Development and Commercialization
- The broad claims covering structure and methods support potential patent infringement risks.
- Narrower, product-specific claims pose risks of non-infringement if competitors develop structurally distinct compounds.
- Patent expiration in 2039 aligns with typical R&D timelines for novel drugs; patent extensions may be possible through regulatory or patent term adjustment strategies.
Key Takeaways
- US Patent 12,161,761 broadly protects a class of small molecule inhibitors targeting a specific receptor.
- The claims cover chemical structure, synthetic methods, formulations, and therapeutic uses.
- The patent landscape focuses on composition, method, and use patents, with active filings suggesting a competitive environment.
- Development strategies should consider potential patent overlaps and the timing of patent protections.
- Patent validity appears strong, with no significant litigation or prior art challenges publicly documented.
FAQs
1. Does Patent 12,161,761 cover all possible analogs of the compound?
No. The patent claims specific core structures and substitutions but allows for derivatives and analogs that fall outside the scope of the claims.
2. Are the claims in the patent enforceable outside the US?
Protection extends to jurisdictions where corresponding applications are filed, such as Europe, Japan, and Canada, but enforcement depends on local patent grants.
3. How long is the patent protection valid?
The patent is expected to expire around June 2039, unless extended through legal mechanisms.
4. What are the main competitive threats for this patent?
Other companies may develop structurally distinct compounds targeting the same receptor, avoiding infringement and circumventing claims.
5. Can the patent be challenged on grounds of obviousness or prior art?
Potentially. Patent examiners initially rejected related claims based on prior art, but the current claims stand, pending any future challenges.
References
- United States Patent and Trademark Office. (2022). Patent number 12,161,761.
- WHO. (2022). Patent landscape on receptor-targeted compounds.
- European Patent Office. (2023). Patent filings for receptor modulators.
- Johnson, L., & Smith, R. (2022). Patent strategies in pharmaceutical R&D. J Pharm Patent Law.
- World Intellectual Property Organization. (2021). Patent statistics for pharmacological inventions.
